Bilateral reduction mammoplasty in a patient treated with calcium channel blocker and cyclosporine after renal transplant: A case report

Transplantation

Volumn 63, Issue 7, 1997, Pages 1032-1033

  Pan, Yang ^a   Grindstaff, Alan ^a   Cassada, David ^a   Goldman, Mitchell ^a   Taylor, James ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; FELODIPINE;

ADULT; ARTICLE; BREAST REDUCTION; CASE REPORT; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; GYNECOMASTIA; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL;

ADULT; BREAST DISEASES; CADAVER; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; FELODIPINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MAMMAPLASTY; PROLACTIN;

EID: 0031001628     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Scott EH. Hypertrophy of the breast, possibly related to medication: a case report. S Afr Med J 1970; 44: 449.
2. Cardon SB, Larson DF, Russell DH. Rapid elevation of rat serum prolactin concentration by cyclosporine, a novel immunosuppressive drug. Biochem Biophys Res Commun 1984; 120: 614.
3. Larson DF, Copeland JG, Russell DH. Prolactin predicts cardiac allograft rejection in cyclosporin immunosuppressed patients [Letter]. Lancet 1985; 6: 53.
4. Mayer G, Kovarik J, Pohanka E, Schwarz M, Graf H, Woloscszuk W. Serum prolactin levels after kidney transplantation. Transplant Proc 1987; 19: 3724.
5. Cowden EA, Ratcliffe WA, Ratcliffe JG, Dobbie JW, Kennedy AC. Hyperprolactinaemia in renal disease. Clin Endocrinol (Oxf) 1978; 9: 241.
6. Keller-Wood M, Bland KI. Breast physiology in normal, lactating and disease states. In: Bland KI, Copeland EM, eds. The breast: comprehensive management of benign and malignant disease. Philadelphia: WB Saunders, 1991: 36.
7. Macleod RM, Foutham EH. Influence of ionic environment on the in vitro synthesis and release of pituitary hormones. Endocrinology 1970; 86: 863.
8. Eto S, Wood JMCM, Hutchins M, Fleischer N. Pituitary 45 Ca++ uptake and release of ACTH, GH and LH: effect of verapamil. Am J Physiol 1970; 226: 1315.
9. Liberman B, Knoepfelmacher M. Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia. Horm Metab Res 1994; 26: 481.
10. Schrey MP, Clark HJ, Franks S. The dopaminergic regulation of anterior pituitary Ca++ homeostasis and prolactin secretion. J Endocrinol 1986; 108: 423.
11. Parsons JA, Nicoll CS. Mechanism of action of prolactin-inhibiting factor. Neuroendocrinology 1971; 8: 213.
12. Nielsen-Kudsk JE, Dalby J. Effects of verapamil on diurnal and thyrotropin-releasing hormone-stimulated prolactin levels in man. J Clin Endocrinol Metab 1990; 70: 1269.
13. Davenport AT, Hodson CA. Effect of cyclosporin treatment on luteinizing hormone and prolactin. Life Sci 1994; 50: 1001.
14. Jacobs U, Klein B, Klehr HU. Cumulative side effects of cyclosporine and Ca antagonists: hypergalactinemia, mastadenoma, and gynecomastia. Transplant Proc 1994; 26: 3122.